# Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

> **NCT00027248** · PHASE3 · COMPLETED · sponsor: **BioWest Therapeutics Inc** · enrollment: 1400 (—)

## Conditions studied

- Sepsis
- Bacteremia
- Fungemia

## Interventions

- **DRUG:** MBI 226

## Key facts

- **NCT ID:** NCT00027248
- **Lead sponsor:** BioWest Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 1400 (—)
- **Last updated:** 2005-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00027248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00027248, "Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00027248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*